Poor response to initial reduction therapy (COP) and combined bone marrow and CNS disease are poor prognostic factors in children with advanced (BM±CNS) B-NHL treated on the international study FAB/LMB96.

被引：0

作者：

Cairo, MS

Gerrard, M

Sposto, R

Auperin, A

Pinkerton, R

Michon, J

Perkins, S

Raphael, M

McCarthy, K

Weston, C

Patte, C

机构：

[1] COG, Arcadia, CA USA

[2] UKCCSG, Leicester, Leics, England

[3] SFOP, Paris, France

来源：

BLOOD | 2003年 / 102卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

492

引用

页码：143A / 143A

页数：1

共 3 条

[1] SURVIVAL IN CHILDREN AND ADOLESCENTS (C plus A) WITH MATURE B-NHL PROGRESSING OR RELAPSING FROM TREATMENT ON FAB/LMB 96: TUMOR BURDEN AND TIME TO RELAPSE ARE POOR PROGNOSTIC FACTORS [J].

Cairo, Mitchell S. ;

Sposto, Richard ;

Fan, Jin ;

Gerrard, Mary ;

Auperin, Anne ;

Pinkerton, Ross ;

McCarthy, Keith ;

Raphael, Martine ;

Harrison, Lauren ;

Goldman, Stanton ;

Patte, Catherine .

PEDIATRIC BLOOD & CANCER, 2009, 53 (05) :855-855

[2] Deletion of cranial irradiation and addition of systemic high dose methotrexate and intrathecal chemotherapy results in 70% 4-yr. EFS in children and adolescents with CNS positive B-NHL: Results of International FAB/LMB 96 study [J].

Cairo, M ;

Gerrard, M ;

Sposto, R ;

Auperin, A ;

Pinkerton, R ;

Michon, J ;

Weston, C ;

Perkins, S ;

Raphael, M ;

McCarthy, K ;

Patte, C .

ANNALS OF ONCOLOGY, 2005, 16 :62-62

[3] Preliminary Results of the Addition of Rasburicase to the Reduction Cycle and Rituximab to the Induction and Consolidation Cycles of FAB Group C Chemotherapy in Children and Adolescents with Advanced Stage (Bone Marrow +/-CNS) Mature B-Cell Non-Hodgkin Lymphoma (B-NHL): A Children's Oncology Group Report [J].

Goldman, Stanton ;

Lynch, James ;

Harrison, Lauren ;

Gross, Thomas ;

Shiramizu, Bruce ;

Sanger, Warren ;

Perkins, Sherrie L. ;

Cairo, Mitchell S. .

BLOOD, 2009, 114 (22) :48-48

← 1 →